SCHEMBL31460048

SCHEMBL31460048

CN(C)S(=O)(=O)n1cc(C(=O)O)c(Cc2ccccc2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.40
ALDH1A1 P00352 1/20 0.39
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
TSHR P16473 3/20 0.36
HIF1A Q16665 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
HNF4A P41235 1/20 0.35
PTPN1 P18031 3/20 0.34
NOTUM Q6P988 1/20 0.34
PTPN2 P17706 1/20 0.34
PTPN6 P29350 1/20 0.34
ABCC1 P33527 1/20 0.34
MCL1 Q07820 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALKBH1 Q13686 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31459970 0.86 ALDH1A1 (0.42) ALDH1A1TSHRSMN1; SMN2CYP1A2CYP3A4
SCHEMBL31460256 0.77 METAP2 (0.33) ALDH1A1TSHRSMN1; SMN2
SCHEMBL17868978 0.77 TSHR (0.43) PPARGPPARATSHRHIF1ASMN1; SMN2
SCHEMBL31460434 0.77 GAA (0.34) ALDH1A1TSHRSMN1; SMN2L3MBTL1
SCHEMBL31460203 0.73 CYP2C19 (0.32) TSHRCYP2C19
SCHEMBL30706927 0.71 NR4A3 (0.44) ALDH1A1PPARGTSHRHIF1ASMN1; SMN2
SCHEMBL28943217 0.71 USP2 (0.41) GLAALDH1A1PPARGPPARAPTPN1
SCHEMBL31459997 0.67 JUN (0.38) GLAALDH1A1TSHRSMN1; SMN2CYP1A2
SCHEMBL15885982 0.65 NAMPT (0.49) ALDH1A1L3MBTL1
SCHEMBL17869011 0.64 MAPT (0.45) ALDH1A1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119677749-A Azaquinazoline pan KRAS inhibitors 米拉蒂治疗股份有限公司 2025-03-21 CN disclosed